Incyte CorporationINCYNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

26 analysts·High coverage

50%

Rating Distribution

Strong Buy

00%

Buy

1350%

Hold

1142%

Sell

28%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 9% higher.

Bear Case

$84.00

-16%

Consensus

$108.90

+9%

Bull Case

$135.00

+35%

Price Range26 analysts

Low

Consensus

High

$84.00

$135.00

Current Target

Current Price

$100.04

Upside to Target

$8.86

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$7.55(14 analysts)

P/E15x

Current: 15.4x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+10.85%

EPS+19.83%

FY2028

Rev+4.56%

EPS+8.29%

FY2029

Rev-29.18%

EPS-62.71%

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:-29.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 18, 2026Barclays

Incyte price target raised to $117 from $116 at Barclays

Target:$117.00

+15.7%from $101.16

Feb 11, 2026Morgan Stanley

Incyte price target raised to $102 from $94 at Morgan Stanley

Target:$102.00

+3.6%from $98.45

Feb 11, 2026Stifel Nicolaus

Incyte price target raised to $120 from $119 at Stifel

Target:$120.00

+19.9%from $100.05

Feb 6, 2026Piper Sandler

Incyte price target raised to $110 from $102 at Piper Sandler

Target:$110.00

+7.0%from $102.76

Feb 5, 2026H.C. Wainwright

Incyte initiated with a Buy at H.C. Wainwright

Target:$135.00

+31.6%from $102.60

Feb 4, 2026Barclays

Incyte price target raised to $116 from $115 at Barclays

Target:$116.00

+14.9%from $100.92

Jan 20, 2026Wells Fargo

Incyte downgraded to Equal Weight from Overweight at Wells Fargo

Target:$107.00

+0.7%from $106.21

Jan 8, 2026Goldman Sachs

Incyte price target raised to $90 from $80 at Goldman Sachs

Target:$90.00

-18.6%from $110.57

Jan 5, 2026Stifel Nicolaus

Stifel Reiterates Buy Rating on Incyte (INCY)

Target:$119.00

+16.9%from $101.79

Dec 24, 2025Truist Financial

Incyte price target raised to $103 from $93 at Truist

Target:$103.00

+2.1%from $100.91

Dec 8, 2025Morgan Stanley

Incyte price target raised to $92 from $86 at Morgan Stanley

Target:$92.00

-4.6%from $96.47

Dec 8, 2025Wells Fargo

Incyte price target raised to $116 from $97 at Wells Fargo

Target:$116.00

+13.1%from $102.52

Dec 8, 2025Mizuho Securities

Incyte upgraded to Outperform from Neutral at Mizuho

Target:$121.00

+18.0%from $102.52

Nov 24, 2025Barclays

Incyte price target raised to $115 from $101 at Barclays

Target:$115.00

+12.7%from $102.06

Nov 4, 2025Piper Sandler

Incyte price target raised to $102 from $82 at Piper Sandler

Target:$102.00

-0.3%from $102.35

Oct 29, 2025Truist Financial

Incyte price target raised to $93 from $79 at Truist

Target:$93.00

+2.9%from $90.35

Oct 29, 2025RBC Capital

Incyte price target raised to $84 from $81 at RBC Capital

Target:$84.00

-8.3%from $91.65

Oct 29, 2025Wells Fargo

Incyte price target raised to $97 from $89 at Wells Fargo

Target:$97.00

+5.4%from $92.02

Oct 29, 2025Barclays

Incyte price target raised to $101 from $90 at Barclays

Target:$101.00

+10.2%from $91.65

Jul 30, 2025UBS

Incyte price target raised to $68 from $62 at UBS

Target:$68.00

-12.3%from $77.55

Jun 23, 2025RBC Capital

J&J's '968 delay has mixed readthroughs for Incyte's '989, says RBC

Target:$67.00

-0.4%from $67.26

Mar 18, 2025Guggenheim

Guggenheim downgrades Incyte on povorcitinib's 'somewhat underwhelming' profile

Target:$92.00

+53.3%from $60.00

Oct 30, 2024Seaport Global

This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday

Target:$200.00

+174.0%from $73.00

Oct 30, 2024Oppenheimer

Incyte price target raised to $82 from $81 at Oppenheimer

Target:$82.00

+11.4%from $73.60

Oct 30, 2024Citigroup

Incyte (INCY) PT Raised to $97 at Citi

Target:$97.00

+31.8%from $73.60

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance